Ziltivekimab
Monoclonal antibody
Type?
TargetInterleukin 6
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Ziltivekimab is a fully human monoclonal antibody against interleukin 6. It is developed by Novo Nordisk to treat heart failure. In clinical trials, levels of high-sensitivity C-reactive protein were reduced in people taking the drug.[1][2][3][4][5][6] The drug has also been tested in chronic kidney disease.[7]

References

  1. ↑ Wada, Yukihiro; Jensen, Camilla; Meyer, Anna Sina Pettersson; Zonoozi, Amir Abbas Mohseni; Honda, Hirokazu (October 2023). "Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): A randomized, double-blind, placebo-controlled, phase 2 trial". Journal of Cardiology. 82 (4): 279–285. doi:10.1016/j.jjcc.2023.05.006.
  2. ↑ Adamstein, Nicholas H.; Cornel, Jan Hein; Davidson, Michael; Libby, Peter; de Remigis, Alessandra; Jensen, Camilla; Ekström, Kathrine; Ridker, Paul M (1 February 2023). "Association of Interleukin 6 Inhibition With Ziltivekimab and the Neutrophil-Lymphocyte Ratio: A Secondary Analysis of the RESCUE Clinical Trial". JAMA Cardiology. 8 (2): 177. doi:10.1001/jamacardio.2022.4277.
  3. ↑ Pergola, Pablo E.; Devalaraja, Matt; Fishbane, Steven; Chonchol, Michel; Mathur, Vandana S.; Smith, Mark T.; Lo, Larry; Herzog, Kurt; Kakkar, Rahul; Davidson, Michael H. (January 2021). "Ziltivekimab for Treatment of Anemia of Inflammation in Patients on Hemodialysis: Results from a Phase 1/2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial". Journal of the American Society of Nephrology. 32 (1): 211–222. doi:10.1681/ASN.2020050595. PMC 7894678. PMID 33272965.
  4. ↑ Ridker, Paul M; Devalaraja, Matt; Baeres, Florian M M; Engelmann, Mads D M; Hovingh, G Kees; Ivkovic, Milana; Lo, Larry; Kling, Douglas; Pergola, Pablo; Raj, Dominic; Libby, Peter; Davidson, Michael (May 2021). "IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial". The Lancet. 397 (10289): 2060–2069. doi:10.1016/S0140-6736(21)00520-1.
  5. ↑ Wada, Y; Jensen, C; Meyer, S; Yamamoto, Y; Honda, H (3 October 2022). "Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial". European Heart Journal. 43 (Supplement_2). doi:10.1093/eurheartj/ehac544.2618.
  6. ↑ Adamstein, N; Cornel, J; Davidson, M; Libby, P; De Remigis, A; Jensen, C; Rajan, S; Ridker, P (3 October 2022). "The effect of ziltivekimab on the neutrophil-lymphocyte ratio: analysis from RESCUE". European Heart Journal. 43 (Supplement_2). doi:10.1093/eurheartj/ehac544.2290.
  7. ↑ Nowak, Kristen L.; Kakkar, Rahul; Devalaraja, Matt; Lo, Larry; Park, Wansu; Gobburu, Joga; Kling, Douglas; Davidson, Michael; Chonchol, Michel (February 2021). "A Phase 1 Randomized Dose-Escalation Study of a Human Monoclonal Antibody to IL-6 in CKD". Kidney360. 2 (2): 224–235. doi:10.34067/KID.0005862020. PMC 8741001.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.